Natco Pharma · NSE: NATCOPHARM · BSE: 524816
Q4 FY25 results · Jan–Mar 2025
Natco Pharma reported revenue from operations of ₹1,221.00 crore (up 14.3% from Q4 FY24) and net profit of ₹406.00 crore (up 5.1% from Q4 FY24) for Q4 FY25 (Jan–Mar 2025), on a consolidated basis.
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,221.00 | 1,068.30 | +14.3% | 474.80 | +157.2% |
| Other income | 66.30 | 42.00 | +57.9% | 176.30 | −62.4% |
| Total income | 1,287.30 | 1,110.30 | +15.9% | 651.10 | +97.7% |
| Profit before tax | 505.90 | 477.60 | +5.9% | 163.70 | +209.0% |
| Net profit for the period | 406.00 | 386.30 | +5.1% | 132.40 | +206.6% |
| Attributable to shareholders of the company | 406.60 | 386.30 | +5.3% | 133.00 | +205.7% |
| EPS, basic (₹) | 22.70 | 21.56 | +5.3% | 7.43 | +205.5% |
| Net margin (%) | 33.3 | 36.2 | 27.9 |
| Item | Q4 FY25 | Q4 FY24 | YoY | Q3 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,157.40 | 964.80 | +20.0% | 407.60 | +184.0% |
| Other income | 62.10 | 35.90 | +73.0% | 168.00 | −63.0% |
| Total income | 1,219.50 | 1,000.70 | +21.9% | 575.60 | +111.9% |
| Profit before tax | 520.80 | 432.50 | +20.4% | 150.30 | +246.5% |
| Net profit for the period | 428.10 | 349.10 | +22.6% | 124.90 | +242.8% |
| EPS, basic (₹) | 23.90 | 19.49 | +22.6% | 6.97 | +242.9% |
| Net margin (%) | 37.0 | 36.2 | 30.6 |
Consolidated
- Filed with BSE
- 28 May 2025, 17:58 IST
- Board meeting
- 28 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 28 May 2025, 17:58 IST
- Board meeting
- 28 May 2025
- Period
- 01 Jan 2025 to 31 Mar 2025
- Review status
- Audited
- Source
- XBRL filing on BSE